Covance Becomes First CRO to Globally Deliver Innovative Technique for TK/PK Sampling
— Integrated Dried Blood Spot (DBS) TK/PK sampling technique improves data quality with combined GLP toxicology, bioanalytical services —

PRINCETON, NJ, July 31, 2009 — Covance Inc. today announced the addition of a new global integrated service supporting the Dried Blood Spot (DBS) sampling technique with Good Laboratory Practice (GLP) toxicology and bioanalytical analysis. Conforming to the three R's guiding principles of research — reduction, replacement, and refinement — DBS sampling provides higher quality toxicokinetic data while reducing test article, shipping, and storage requirements.

"As the first CRO to globally support the DBS sample technique, this integrated service provides more efficient toxicology and bioanalytical testing to potentially improve data quality," said Steven Michael, vice president and chief scientific officer, global bioanalytical services, Covance. "This service reduces sample volumes, provides a more refined sample collection process, and improved data quality to increase study speed and quality. Covance spent more than a year analyzing thousands of DBS samples from multiple studies to refine the bioanalytical technique."

The DBS sampling technique increases sample handling safety with chemically treated cards that inactivate HIV and Hepatitis B. The technique also enhances compound stability and increases flexibility in study design while providing convenient collection, shipping, and storage of blood samples for toxicokinetic and pharmacokinetic data. DBS also offers clinical advantages as a preferred method of blood collection over venous cannula sampling.

"This new service provides our clients with sound ethical and cost benefits by significantly reducing sample volumes and improving data quality," said Steve Barkyoumb, vice president, North America toxicology, Covance.

Covance offers a dedicated, integrated team of toxicology Study Directors with an average of 15 years of industry experience and bioanalytical scientists with an average of 10 years of industry experience. Covance offers flexible global capacity with facilities located in Chandler, Ariz.; Greenfield, Ind.; Indianapolis, Ind.; Madison, Wis.; Vienna, Va.; Harrogate, United Kingdom; Münster, Germany; and Shanghai, China.

About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.